Induced proximity at the cell surface – Nature Biotechnology
Stanton, B. Z., Chory, E. J. & Crabtree, G. R. Chemically induced proximity in biology and medicine. Science 359, eaao5902 (2018).
Google Scholar
Schapira, M., Calabrese, M. F., Bullock, A. N. & Crews, C. M. Targeted protein degradation: expanding the toolbox. Nat. Rev. Drug Discov. 18, 949–963 (2019).
Google Scholar
Schreiber, S. L. Molecular glues and bifunctional compounds: therapeutic modalities based on induced proximity. Cell Chem. Biol. 31, 1050–1063 (2024).
Google Scholar
Yamazoe, S. et al. Heterobifunctional molecules induce dephosphorylation of kinases—a proof of concept study. J. Med. Chem. 63, 2807–2813 (2020).
Google Scholar
Chen, P.-H. et al. Modulation of phosphoprotein activity by phosphorylation targeting chimeras (PhosTACs). ACS Chem. Biol. 16, 2808–2815 (2021).
Google Scholar
Liu, X. & Ciulli, A. Proximity-based modalities for biology and medicine. ACS Cent. Sci. 9, 1269–1284 (2023).
Google Scholar
Gibson, W. J. et al. Bifunctional small molecules that induce nuclear localization and targeted transcriptional regulation. J. Am. Chem. Soc. 145, 26028–26037 (2023).
Google Scholar
Ng, C. S. C., Liu, A., Cui, B. & Banik, S. M. Targeted protein relocalization via protein transport coupling. Nature 633, 941–951 (2024).
Google Scholar
Banik, S. M. et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584, 291–297 (2020).
Google Scholar
Cotton, A. D., Nguyen, D. P., Gramespacher, J. A., Seiple, I. B. & Wells, J. A. Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1. J. Am. Chem. Soc. 143, 593–598 (2021).
Google Scholar
Marei, H. et al. Antibody targeting of E3 ubiquitin ligases for receptor degradation. Nature 610, 182–189 (2022).
Google Scholar
Wells, J. A. & Kumru, K. Extracellular targeted protein degradation: an emerging modality for drug discovery. Nat. Rev. Drug Discov. 23, 126–140 (2024).
Google Scholar
Mullard, A. First targeted protein degrader hits the clinic. Nat. Rev. Drug Discov. 18, 237–239 (2019).
Google Scholar
Mullard, A. Targeted protein degraders crowd into the clinic. Nat. Rev. Drug Discov. 20, 247–250 (2021).
Google Scholar
Ahn, G. et al. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat. Chem. Biol. 17, 937–946 (2021).
Google Scholar
Pance, K. et al. Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins. Nat. Biotechnol. 41, 273–281 (2023).
Google Scholar
Ghosh, P., Dahms, N. M. & Kornfeld, S. Mannose 6-phosphate receptors: new twists in the tale. Nat. Rev. Mol. Cell Biol. 4, 202–213 (2003).
Google Scholar
Caianiello, D. F. et al. Bifunctional small molecules that mediate the degradation of extracellular proteins. Nat. Chem. Biol. 17, 947–953 (2021).
Google Scholar
Zhou, Y., Teng, P., Montgomery, N. T., Li, X. & Tang, W. Development of triantennary N-acetylgalactosamine conjugates as degraders for extracellular proteins. ACS Cent. Sci. 7, 499–506 (2021).
Google Scholar
Gramespacher, J. A., Cotton, A. D., Burroughs, P. W. W., Seiple, I. B. & Wells, J. A. Roadmap for optimizing and broadening antibody-based PROTACs for degradation of cell surface proteins. ACS Chem. Biol. 17, 1259–1268 (2022).
Google Scholar
Siepe, D. H., Picton, L. K. & Garcia, K. C. Receptor elimination by E3 ubiquitin ligase recruitment (REULR): a targeted protein degradation toolbox. ACS Synth. Biol. 12, 1081–1093 (2023).
Google Scholar
Lau de, W., Peng, W. C., Gros, P. & Clevers, H. The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength. Genes Dev. 28, 305–316 (2014).
Google Scholar
Sampathkumar, P. et al. Targeted protein degradation systems to enhance Wnt signaling. eLife 13, RP93908 (2024).
Google Scholar
Zheng, J. et al. Bifunctional compounds as molecular degraders for integrin-facilitated targeted protein degradation. J. Am. Chem. Soc. 144, 21831–21836 (2022).
Google Scholar
Morimoto, M., Till, N. A. & Bertozzi, C. R. Tumor immune cell targeting chimeras (TICTACs) for targeted depletion of macrophage-associated checkpoint receptors. Preprint at bioRxiv https://doi.org/10.1101/2023.12.06.570444 (2023).
Dovedi, S. J. et al. Design and efficacy of a monovalent bispecific PD-1/CTLA4 antibody that enhances CTLA4 blockade on PD-1+ activated T cells. Cancer Discov. 11, 1100–1117 (2021).
Google Scholar
Moores, S. L. et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res. 76, 3942–3953 (2016).
Google Scholar
Ludwig, S. D. et al. Multiparatopic antibodies induce targeted downregulation of programmed death-ligand 1. Cell Chem. Biol. 31, 904–919 (2024).
Google Scholar
Chen, S., Cui, J., Chen, H., Yu, B. & Long, S. Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques. Eur. J. Med. Chem. 262, 115911 (2023).
Google Scholar
Chen, X., Zhou, Y., Zhao, Y. & Tang, W. Targeted degradation of extracellular secreted and membrane proteins. Trends Pharmacol. Sci. 44, 762–775 (2023).
Google Scholar
Ahn, G., Banik, S. M. & Bertozzi, C. R. Degradation from the outside in: targeting extracellular and membrane proteins for degradation through the endolysosomal pathway. Cell Chem. Biol. 28, 1072–1080 (2021).
Google Scholar
Zhang, D. et al. Transferrin receptor targeting chimeras for membrane protein degradation. Nature 638, 787–795 (2025).
Sibley, D. R., Benovic, J. L., Caron, M. G. & Lefkowitz, R. J. Phosphorylation of cell surface receptors: a mechanism for regulating signal transduction pathways. Endocr. Rev. 9, 38–56 (1988).
Google Scholar
Billadeau, D. D. & Leibson, P. J. ITAMs versus ITIMs: striking a balance during cell regulation. J. Clin. Invest. 109, 161–168 (2002).
Google Scholar
Chakraborty, A. K. & Weiss, A. Insights into the initiation of TCR signaling. Nat. Immunol. 15, 798–807 (2014).
Google Scholar
Monroe, J. G. ITAM-mediated tonic signalling through Pre-BCR and BCR complexes. Nat. Rev. Immunol. 6, 283–294 (2006).
Google Scholar
Ben Mkaddem, S., Benhamou, M. & Monteiro, R. C. Understanding Fc receptor involvement in inflammatory diseases: from mechanisms to new therapeutic tools. Front. Immunol. 10, 811 (2019).
Google Scholar
Suber, J. & Iweala, O. I. Strategies for mast cell inhibition in food allergy. Yale J. Biol. Med. 93, 719–731 (2020).
Google Scholar
Gomez, G. Current strategies to inhibit high affinity FcεRI-mediated signaling for the treatment of allergic disease. Front. Immunol. 10, 175 (2019).
Google Scholar
Zhu, D., Kepley, C. L., Zhang, M., Zhang, K. & Saxon, A. A novel human immunoglobulin Fcγ–Fcɛ bifunctional fusion protein inhibits FcɛRI-mediated degranulation. Nat. Med. 8, 518–521 (2002).
Google Scholar
Daëron, M. et al. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc γ RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 3, 635–646 (1995).
Google Scholar
Turner, H. & Kinet, J.-P. Signalling through the high-affinity IgE receptor FcεRI. Nature 402, 24–30 (1999).
Google Scholar
Tam, S. W., Demissie, S., Thomas, D. & Daëron, M. A bispecific antibody against human IgE and human FcγRII that inhibits antigen-induced histamine release by human mast cells and basophils. Allergy 59, 772–780 (2004).
Google Scholar
Zhu, D. et al. A chimeric human–cat fusion protein blocks cat-induced allergy. Nat. Med. 11, 446–449 (2005).
Google Scholar
Eggel, A. et al. Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin–Fc fusion protein. Allergy 66, 961–968 (2011).
Google Scholar
Zellweger, F. et al. A novel bispecific DARPin targeting FcγRIIB and FcεRI-bound IgE inhibits allergic responses. Allergy 72, 1174–1183 (2017).
Google Scholar
Veri, M.-C. et al. Therapeutic control of B cell activation via recruitment of Fcγ receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum. 62, 1933–1943 (2010).
Google Scholar
Karnell, J. L. et al. CD19 and CD32b differentially regulate human B cell responsiveness. J. Immunol. 192, 1480–1490 (2014).
Google Scholar
Chu, S. Y. et al. Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor. Arthritis Rheumatol. 66, 1153–1164 (2014).
Google Scholar
Perugino, C. A. et al. Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial. Lancet Rheumatol. 5, e442–e450 (2023).
Google Scholar
Crocker, P. R., Paulson, J. C. & Varki, A. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7, 255–266 (2007).
Google Scholar
Paul, S. P., Taylor, L. S., Stansbury, E. K. & McVicar, D. W. Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 96, 483–490 (2000).
Google Scholar
McCord, K. A. et al. Dissecting the ability of Siglecs to antagonize Fcγ receptors. ACS Cent. Sci. 10, 315–330 (2024).
Google Scholar
Ikehara, Y., Ikehara, S. K. & Paulson, J. C. Negative regulation of T cell receptor signaling by Siglec-7 (P70/AIRM) and Siglec-9. J. Biol. Chem. 279, 43117–43125 (2004).
Google Scholar
Enterina, J. R., Jung, J. & Macauley, M. S. Coordinated roles for glycans in regulating the inhibitory function of CD22 on B cells. Biomed. J. 42, 218–232 (2019).
Google Scholar
Movsisyan, L. D. & Macauley, M. S. Structural advances of Siglecs: insight into synthetic glycan ligands for immunomodulation. Org. Biomol. Chem. 18, 5784–5797 (2020).
Google Scholar
Macauley, M. S. et al. Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis. J. Clin. Invest. 123, 3074–3083 (2013).
Google Scholar
Duong, B. H. et al. Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo. J. Exp. Med. 207, 173–187 (2009).
Google Scholar
Orgel, K. A. et al. Exploiting CD22 on antigen-specific B cells to prevent allergy to the major peanut allergen Ara h 2. J. Allergy Clin. Immunol. 139, 366–369 (2017).
Google Scholar
Niiro, H. & Clark, E. A. Regulation of B-cell fate by antigen-receptor signals. Nat. Rev. Immunol. 2, 945–956 (2002).
Google Scholar
Islam, M. et al. Suppressing immune responses using Siglec ligand-decorated anti-receptor antibodies. J. Am. Chem. Soc. 144, 9302–9311 (2022).
Google Scholar
Duan, S. et al. CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen. J. Clin. Invest. 129, 1387–1401 (2021).
Google Scholar
Duan, S. et al. Nanoparticles displaying allergen and Siglec-8 ligands suppress IgE–FcεRI-mediated anaphylaxis and desensitize mast cells to subsequent antigen challenge. J. Immunol. 206, 2290–2300 (2021).
Google Scholar
Fernandes, R. A. et al. Immune receptor inhibition through enforced phosphatase recruitment. Nature 586, 779–784 (2020).
Google Scholar
Patsoukis, N., Wang, Q., Strauss, L. & Boussiotis, V. A. Revisiting the PD-1 pathway. Sci. Adv. 6, eabd2712 (2020).
Google Scholar
Ren, J. et al. Induced CD45 proximity potentiates natural killer cell receptor antagonism. ACS Synth. Biol. 11, 3426–3439 (2022).
Google Scholar
Finney, H. M., Rapecki, S. E., Wright, M. J. & Tyson, K. L. Molecules with specificity for CD45 and CD79. US patent US10774152B2 (2020).
Wu, S. et al. Aptamer-based enforced phosphatase-recruiting chimeras inhibit receptor tyrosine kinase signal transduction. J. Am. Chem. Soc. 146, 22445–22454 (2024).
Google Scholar
Schmid, E. M. et al. Size-dependent protein segregation at membrane interfaces. Nat. Phys. 12, 704–711 (2016).
Google Scholar
Waldmann, T. A. Cytokines in cancer immunotherapy. Cold Spring Harb. Perspect. Biol. 10, a028472 (2018).
Google Scholar
Saxton, R. A., Glassman, C. R. & Garcia, K. C. Emerging principles of cytokine pharmacology and therapeutics. Nat. Rev. Drug Discov. 22, 21–37 (2023).
Google Scholar
Liu, J. et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct. Target. Ther. 7, 3 (2022).
Google Scholar
Goetz, R. & Mohammadi, M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat. Rev. Mol. Cell Biol. 14, 166–180 (2013).
Google Scholar
Lai, Y. & Dong, C. Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases. Int. Immunol. 28, 181–188 (2016).
Google Scholar
Kim, G. W. et al. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Arch. Pharm. Res. 38, 575–584 (2015).
Google Scholar
Hernandez, R., Põder, J., LaPorte, K. M. & Malek, T. R. Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat. Rev. Immunol. 22, 614–628 (2022).
Google Scholar
Junttila, I. S. et al. Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines. Nat. Chem. Biol. 8, 990–998 (2012).
Google Scholar
Harris, K. E. et al. A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells. Sci. Rep. 11, 10592 (2021).
Google Scholar
Yen, M. et al. Facile discovery of surrogate cytokine agonists. Cell 185, 1414–1430 (2022).
Google Scholar
Romei, M. G. et al. i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists. Nat. Commun. 15, 642 (2024).
Google Scholar
Sonoda, J., Chen, M. Z. & Baruch, A. FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases. Horm. Mol. Biol. Clin. Investig. 30, 20170002 (2017).
Geng, L., Lam, K. S. L. & Xu, A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat. Rev. Endocrinol. 16, 654–667 (2020).
Google Scholar
Fon Tacer, K. et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol. Endocrinol. 24, 2050–2064 (2010).
Google Scholar
Xie, Y. et al. FGF/FGFR signaling in health and disease. Signal Transduct. Target. Ther. 5, 181 (2020).
Google Scholar
Véniant, M. M. et al. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 153, 4192–4203 (2012).
Google Scholar
Smith, R. et al. FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c/β-klotho bispecific protein. PLoS ONE 8, e61432 (2013).
Google Scholar
Kolumam, G. et al. Sustained brown fat stimulation and insulin sensitization by a humanized bispecific antibody agonist for fibroblast growth factor receptor 1/βklotho complex. eBioMedicine 2, 730–743 (2015).
Google Scholar
Ming, A. Y. K. et al. Dynamics and distribution of klothoβ (KLB) and fibroblast growth factor receptor-1 (FGFR1) in living cells reveal the fibroblast growth factor-21 (FGF21)-induced receptor complex. J. Biol. Chem. 287, 19997–20006 (2012).
Google Scholar
Wong, C. et al. Fibroblast growth factor receptor 1/klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: a phase 1b randomized trial. Hepatology 78, 847–862 (2023).
Google Scholar
Gordon, M. D. & Nusse, R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J. Biol. Chem. 281, 22429–22433 (2006).
Google Scholar
Clevers, H., Loh, K. M. & Nusse, R. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science 346, 1248012 (2014).
Google Scholar
Post, Y. et al. Design principles and therapeutic applications of novel synthetic WNT signaling agonists. iScience 27, 109938 (2024).
Google Scholar
Janda, C. Y. et al. Surrogate Wnt agonists that phenocopy canonical Wnt and β-catenin signalling. Nature 545, 234–237 (2017).
Google Scholar
Tao, Y. et al. Tailored tetravalent antibodies potently and specifically activate Wnt/Frizzled pathways in cells, organoids and mice. eLife 8, e46134 (2019).
Google Scholar
Miao, Y. et al. Next-generation surrogate Wnts support organoid growth and deconvolute Frizzled pleiotropy in vivo. Cell Stem Cell 27, 840–851 (2020).
Google Scholar
Chen, H. et al. Development of potent, selective surrogate WNT molecules and their application in defining Frizzled requirements. Cell Chem. Biol. 27, 598–609 (2020).
Google Scholar
Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B. & Gloriam, D. E. Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov. 16, 829–842 (2017).
Google Scholar
Rankovic, Z., Brust, T. F. & Bohn, L. M. Biased agonism: an emerging paradigm in GPCR drug discovery. Bioorg. Med. Chem. Lett. 26, 241–250 (2016).
Google Scholar
Sachdev, S., Creemer, B. A., Gardella, T. J. & Cheloha, R. W. Highly biased agonism for GPCR ligands via nanobody tethering. Nat. Commun. 15, 4687 (2024).
Google Scholar
Cheloha, R. W., Gellman, S. H., Vilardaga, J.-P. & Gardella, T. J. PTH receptor-1 signalling—mechanistic insights and therapeutic prospects. Nat. Rev. Endocrinol. 11, 712–724 (2015).
Google Scholar
Goebeler, M.-E. & Bargou, R. C. T cell-engaging therapies — BiTEs and beyond. Nat. Rev. Clin. Oncol. 17, 418–434 (2020).
Google Scholar
You, G. et al. Bispecific antibodies: a smart arsenal for cancer immunotherapies. Vaccines 9, 724 (2021).
Google Scholar
Huehls, A. M., Coupet, T. A. & Sentman, C. L. Bispecific T-cell engagers for cancer immunotherapy. Immunol. Cell Biol. 93, 290–296 (2015).
Google Scholar
Zhao, S. et al. Gnawing between cells and cells in the immune system: friend or foe? A review of trogocytosis. Front. Immunol. 13, 791006 (2022).
Google Scholar
Li, K.-J. et al. Trogocytosis between non-immune cells for cell clearance, and among immune-related cells for modulating immune responses and autoimmunity. Int. J. Mol. Sci. 22, 2236 (2021).
Google Scholar
Joly, E. & Hudrisier, D. What is trogocytosis and what is its purpose? Nat. Immunol. 4, 815 (2003).
Google Scholar
Till, N., Ramanathan, M., Loh, K. Y. & Bertozzi, C. Trogocytosis targeting chimeras (TrogoTACs) for targeted protein transfer. Preprint at ChemRxiv https://doi.org/10.26434/chemrxiv-2024-k7kn2-v2 (2024).
